ASCO 2018: highlights in HER2-positive metastatic breast cancer

At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate the future directions of drug development in this field. Early phase studies with novel antibody-drug conjug...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartsch, Rupert, Bergen, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280772/
https://www.ncbi.nlm.nih.gov/pubmed/30595754
http://dx.doi.org/10.1007/s12254-018-0441-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280772/
https://www.ncbi.nlm.nih.gov/pubmed/30595754
http://dx.doi.org/10.1007/s12254-018-0441-x

Ejemplares similares